Cipher Pharmaceuticals (CPH.TO) Stock Price
Cipher Pharmaceuticals Price
Revenue has compounded at 24.7% per year over the past 19 years to 51.33 M USD. Earnings per share have grown at 51.6% per year over the last 15 years. Cipher Pharmaceuticals's net margin stands at 54.2%, up from 35.4% several years earlier. Analysts set a median price target of 13.72 USD, implying 45.3% above the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.
Cipher Pharmaceuticals stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cipher Pharmaceuticals business model & stock analysis
Frequently asked questions about Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc. operates as a pharmaceutical company. Their business model focuses on developing, acquiring, and commercializing novel prescription products for targeted therapeutic areas. With a focus on dermatology, they aim to provide innovative solutions to patients and healthcare professionals. Cipher Pharmaceuticals Inc. leverages its expertise in drug formulation and product commercialization to bring high-quality, differentiated treatments to market. Their commitment to research and development, along with strategic partnerships, positions them as a trusted provider of specialized pharmaceutical products.
Cipher Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
Cipher Pharmaceuticals Inc faces competition from several key players in the market. Some of the main competitors include [competitor 1], [competitor 2], and [competitor 3]. These companies operate in the same industry as Cipher Pharmaceuticals Inc and offer similar products and services. While Cipher Pharmaceuticals Inc has established a strong presence in the market with their innovative solutions, they must continuously strive to stay ahead of the competition and adapt to changing market dynamics.
Cipher Pharmaceuticals Inc. is a renowned Canadian pharmaceutical company with a rich history and established background. Founded in 2000, Cipher focuses on the development and commercialization of innovative prescription products. With a diverse portfolio ranging from dermatology to cardiometabolic disorders, Cipher has gained a strong foothold in the global pharmaceutical market. The company's strategic partnerships and collaborations have propelled its growth and allowed it to bring new treatments to market. Known for its commitment to excellence, Cipher Pharmaceuticals Inc. continues to make significant contributions to the healthcare industry, delivering high-quality products and improving patients' lives worldwide.
Cipher Pharmaceuticals Inc has achieved several significant milestones throughout its history. One notable milestone was the acquisition of Innocutis Holdings LLC in 2014, expanding its product portfolio and market reach. In addition, Cipher successfully secured partnerships and licensing agreements for its pharmaceutical products, strengthening its global presence. The company's focused approach and commitment to research and development have also led to the successful launch of innovative products in various therapeutic areas. Furthermore, Cipher Pharmaceuticals Inc has consistently demonstrated strong financial performance, achieving steady revenue growth and profitability over the years. These achievements highlight the company's dedication towards delivering high-quality pharmaceutical solutions to improve patient outcomes.
Cipher Pharmaceuticals Inc is primarily present in several countries and regions around the world. Some of the key markets where the company operates include Canada and the United States. The company has a significant presence and a strong focus on the North American pharmaceutical market. With its headquarters in Mississauga, Ontario, Cipher Pharmaceuticals Inc also has a presence in various countries globally, including Europe, Latin America, and other international markets. The company's global reach allows it to cater to a diverse range of patients and healthcare professionals, ensuring widespread access to its innovative pharmaceutical products.
Cipher Pharmaceuticals Inc is a company that firmly believes in values such as integrity, innovation, and excellence. With a strong corporate philosophy, Cipher strives to provide healthcare solutions that cater to the diverse needs of patients worldwide. By consistently adopting cutting-edge technologies and research, Cipher is committed to delivering high-quality products that improve patients' quality of life. With a customer-centric approach, the company focuses on building strong relationships with healthcare professionals and stakeholders to ensure the best outcomes. Cipher Pharmaceuticals Inc's dedication to ethical practices and continuous improvement makes it a trusted player in the pharmaceutical industry.
Analysts currently set an average price target of 13.86 USD for the Cipher Pharmaceuticals stock (median: 13.72 USD), implying +46.8 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the Cipher Pharmaceuticals stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Cipher Pharmaceuticals to generate revenue of 47.54 M USD and earnings per share of 0.73 USD.
Converted at the current exchange rate, the Cipher Pharmaceuticals share trades at 8.41 EUR (9.44 USD).
The Cipher Pharmaceuticals share (CPH.TO) is listed on 4 stock exchanges, including: Toronto (CPH.TO), Frankfurt (PHE.F), München (PHE.MU).
Cipher Pharmaceuticals Inc is a Canadian company specializing in the development, manufacturing, and marketing of pharmaceutical preparations. The company places great emphasis on research and development to create innovative solutions for patients worldwide. Cipher invests in a variety of therapeutic areas, including dermatology, pain medications, urinary tract diseases, and cardiology. There are products developed for acne, eczema, psoriasis, nail fungus, herpes, and more. Cipher Pharmaceuticals has three main business areas in which it operates: 1. Proprietary Products This business segment focuses on the development and marketing of patented drugs for patients worldwide. The company is strong in dermatology and offers innovative products for skin diseases such as acne, eczema, and psoriasis. An example of a patented product from Cipher is the medical gel Absorica for acne. The patented technology ensures controlled release of isotretinoin, an active ingredient known for its effectiveness in severe acne. 2. In-Licensing and Acquisitions Cipher Pharmaceuticals is also active in the in-licensing and acquisition market. The company acquires the rights to drugs from other companies that are either on the market or still in the development phase. Through this business segment, Cipher gains access to new technologies and drug products that can complement the company's product portfolio. Cipher also seeks partnerships and joint ventures to further grow and expand. 3. Licensing Cipher Pharmaceuticals also offers licenses for its technologies and products on the global market. Cipher has partnerships in European countries, Canada, and the United States. Cipher continuously invests in research and development to create innovative drugs for patients. The company aims to reformulate active ingredients such as isotretinoin to improve their effectiveness while reducing side effects. Overall, Cipher Pharmaceuticals is an innovative, research-based company. The development of patented medications as well as in-licensing and acquisitions enable the company to expand its product portfolio and fulfill its vision of supporting patients.
The expected revenue of Cipher Pharmaceuticals is 47.54 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Cipher Pharmaceuticals is 19.16 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Cipher Pharmaceuticals is currently 12.86. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cipher Pharmaceuticals stock.
The price-to-sales ratio (P/S) of Cipher Pharmaceuticals is currently 5.18. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cipher Pharmaceuticals stock.
The Eulerpool Quality Score for Cipher Pharmaceuticals is 5/10.
The ISIN of Cipher Pharmaceuticals is CA17253X1050. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Cipher Pharmaceuticals is A0B85L. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Cipher Pharmaceuticals is CPH.TO. The ticker symbol is used to trade Cipher Pharmaceuticals shares on the stock exchange.
Cipher Pharmaceuticals stock
Cipher Pharmaceuticals Peer Group
Cipher Pharmaceuticals Ticker
Cipher Pharmaceuticals FIGI
All fundamentals and in-depth analysis of Cipher Pharmaceuticals
Our stock analysis for Cipher Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cipher Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.